Incorporating AI Into Drug Discovery
Product News Oct 10, 2019
Optibrium™, a developer of software for drug discovery has announced the introduction of its Augmented Chemistry™ services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to make more effective decisions and advance their drug discovery projects.
Augmented Chemistry™ services are built on a unique deep learning capability for data imputation, Alchemite™, which has been developed in collaboration with Intellegens Limited. Alchemite™ learns simultaneously across all experimental endpoints in a project or corporate database, even based on limited data. The resulting model can automatically highlight the most confident, and therefore accurate, predictions on which to base experimental decisions, including the identification of new or previously overlooked high-quality compounds.